Oncopeptides (Q2 Initial take): Solid 23% Q/Q Growth - Redeye

Redeye provides its first take on Oncopeptides' Q2 report 2026. Sales grew 23% versus Q1 2026. Operating costs amounted to SEK-79m, with an EBIT of SEK-49m. The topline was above our expectations, which is important, though EBIT below due to higher OPEX, which overall suggests a positive share reaction when the market opens.

Länk till analysen i sin helhet: https://www.redeye.se/research/1182339/oncopeptides-q2-initial-take-solid-23-q-q-growth?utm_source=finwire&utm_medium=RSS